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Objectives. Using prospectively collected registry data to investigate sick leave (sickness benefit and sickness compensation) over a 7-yr
period in patients with AS in comparison with population-based controls matched for age, sex and residential area.
Methods. We investigated 122 (21 women and 101 men) outpatients with AS in South Sweden, born 1942 or later, from rheumatology
specialist care for their sick leave during a 7-yr period. Mean (S.D.) age was 43 (11)yrs and mean (S.D.) disease duration was 20 (11)yrs. Two
controls per case, matched for age, sex and residential area were selected from the Swedish National Population Register. Data concerning
sick leave for cases and controls, based on the subjects’ unique 10-digit personal identification number, were retrieved from the national
register of the Swedish Social Insurance Agency.
Results. More AS patients than controls were registered for sickness benefit (52 vs 36%, P<0.01) and sickness compensation (42 vs 11%,
P<0.001). Cases had an increased risk for sick leave compared with controls with a relative risk of 1.8; 95% CI 1.5, 2.1; and cases had more
days with sick leave than controls (median number of more days per year 30; 95% CI 2, 72).
Conclusions. Using the Swedish Social Insurance Agency’s registers for sick leave, we found that patients with AS in rheumatology
specialist care in South Sweden have an increased level of sick leave compared with controls. These population-based registers have a great
potential for studies of the effects of different interventions on sick leave.
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Introduction
AS is a chronic, inflammatory rheumatic disease with an unknown
aetiology. Prevalence and incidence in the western world are
estimated at 0.2% and 6/100000 per year, respectively, and the
disease is more prevalent among men [1]. The disease usually
starts between 15 and 30yrs of age. Disease manifestations, such
as pain and stiffness in the axial skeleton and in some cases also
peripheral arthritis, enthesitis and extra-articular manifestations,
contribute to impairment, activity limitation, participation restric-
tion and reduced quality of life [2–4]. Reduced work ability lead-
ing to sick leave is a common consequence of AS [5, 6] and may
contribute to psychosocial and financial (direct and indirect)
sequels for the individual as well as for the society [7, 8]. For
decades the most common treatment for AS was NSAIDs and
physical therapy. The treatment options have recently been broad-
ened by TNF inhibitors with beneficial effect on disease activity,
function, sick leave and quality of life [9–11]. Employment status
in patients with AS of varying disease duration ranges between
55 and 89% in different countries [12]. Proportion of work-
disabled patients with AS is reported to vary between 9 and 36%
[12]. Differences seen in employment status and work disability
between countries may be partly due to differences in social
security systems and different labour markets [12]. The main
purpose of this registry-based case–control study was to investi-
gate sick leave over a 7-yr period in a cohort of patients with AS
in Malmo ¨ , South Sweden, compared with controls matched for
age, sex and residential area. The Swedish Social Insurance
Agency continuously registers compensation for sick leave paid to
all residents by their unique personal identification number,
and cross-referencing this registry with a disease cohort may
provide the foundation for high-quality research on sick leave and
health economics.
Subjects and methods
Definitions
According to the Swedish legislation, all residents aged 16–64yrs
can be granted economic security from the Swedish Social Insur-
ance Agency in the event of work incapacity owing to sickness,
disability or injuries [13]. Different forms of benefit are sick pay,
sickness benefit and sickness compensation, which are all income-
related benefits (Fig. 1).
The waiting period or the qualifying day is the first day of illness.
No benefit is paid for this day.
Sick pay is benefit for the 2nd to the 14th days of illness, and is
paid directly from the employer. Sick periods 14 days or shorter
are therefore not registered by the Swedish Social Insurance
Agency.
Sickness benefit is compensation for illness that reduces work
capacity by at least one-quarter for a limited time. It is gener-
ally limited to 1yr, and can be payable as full, three-quarters,
half or one-quarter benefit depending on the reduction in work
capacity. Sickness benefit may be approved from Day 15 of
sick leave.
Sickness compensation (before 2003 referred to as disability
pension) can be granted to insured individuals with a permanent
or long-term (at least 1yr) full or partial incapacity for work due
to illness or some other impairment of their physical or mental
capacity for work. Sickness compensation is paid to insured per-
sons aged 30–64yrs and can be granted for either an indefinite or a
limited period. Sickness compensation is payable as full, three-
quarters, half or one-quarter benefit, depending on the extent of
the reduction in work capacity.
Sick leave is in the present study defined as days with sickness
benefit and days with sickness compensation registered at the
Swedish Social Insurance Agency. The first 14 days of illness
(waiting period/qualifying day and sick pay period) are not
included in the sick leave.
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Entry criteria for the patients included in this study were: men
and women born 1942 or later (465yrs in 2007), living in the
region of Ska ˚ ne in South Sweden, and registered for consultation
at a doctor in the rheumatology specialist care in Malmo ¨ between
1993 and 2006 with diagnosis of AS according to the New York
criteria [14] verified in the patient records. Malmo ¨ is a city in
Ska ˚ ne with a population of 230000 individuals over the age of
15yrs. At the time of inclusion, the rheumatology specialist care
in Malmo ¨ comprised of the Rheumatology Department of the
University Hospital in Malmo ¨ and three rheumatologists prac-
ticing privately in the city. These rheumatology specialists were
connected to the hospital clinic by a special contract and were an
integrated part of the rheumatology service and the rheumatology
team in Malmo ¨ [15].
Patients were identified from the outpatient registers of the
Rheumatology Department of the University Hospital and the
three rheumatologists practicing privately. Patients were included
if they had AS according to ICD-9 (720A) or ICD-10 (M45)
or, when no code was available (in two of the private practices’
registers), a written diagnosis of AS, pelvospondylitis or Mb
Bechterew was present. A total of 158 patients, 120 men and 38
women, were identified. To verify the diagnosis, one of the
authors (B.S.) examined their medical records and found that 36
patients, 19 men and 17 women, did not fulfil the New York
criteria for diagnosis and were excluded. Thus, in all 122 patients,
101 men and 21 women were included in the study. To further
validate and characterize the study sample the prevalence of
uveitis was registered from the medical records and information of
treatment with TNF-inhibitors was collected from the South
Swedish Arthritis Treatment Group (SSATG) register [16]. Using
the National Population Register, we selected two controls per
case matched for age (the same birth date or as close as possible to
the same birth date), sex and residential area (zip code).
For 61 of the 122 patients with AS included in the present
study, disease activity and functional status were assessed in 2004
(a time-point which is included in the follow-up time of the present
study) in an earlier separate project concerning health-related
quality of life in patients with AS (data not published). These 61
patients were included in a post hoc correlation analysis in the
present study (see below).
Sick leave data
Based on the subjects’ unique 10-digit personal identification
number we retrieved data concerning sick leave (number of days
with sickness benefit and number of days with sickness compen-
sation) for cases and controls from the Swedish Social Insurance
Agency. The data included all sick leave for both cases and con-
trols, i.e. for the cases, sick leave was both related and unrelated to
the diagnosis of AS. Data contained dates of sick leave and degree
of sick leave (25, 50, 75 or 100% of the day). The follow-up time
for sick leave of cases and controls was from 1 January 2000 until
31 January 2007. When the follow-up time was interrupted (e.g.
due to death or relocation out of the region) for either a case or
any of its controls, the follow-up time was interrupted for all three
of them, i.e. a case and its two controls always had the same length
of follow-up time.
Correlations
For a post hoc evaluation of the correlation between sick leave and
disease activity and sick leave and functional status, respectively,
we used data from an earlier project for a subgroup (n¼61, see
above) of the 122 patients with AS included in the present study.
The well-validated instruments Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) [17, 18] and Bath Ankylosing
Spondylitis Functional Index (BASFI) [19, 20] were used for
assessment of disease activity and functional status.
Statistical methods
We used the Cochran–Mantel–Haenszel test to evaluate differ-
ences in frequencies of sick leave. For risk analysis of being on
sick leave stratified Cox regression with equal follow up times for
patients and controls and robust variance estimator was used. As
secondary analysis the median of the difference in number of
days on sick leave between patients and controls was counted.
The 95% CI for the median was evaluated using the bootstrap-
ping method with respect to matching [21]. Due to the small
number of women included in the study, the results for men and
women are presented together. Correlations were performed by
using the Spearman rank correlation coefficient (rs). All P-values
were two-tailed and we considered a P-value of 0.05 or less as
statistically significant. Analyses were done using SAS software
9.1, Copyright 2002–03, SAS Institute Inc. and R 2.5.1 (http://
www.r-project.org/).
Ethical approval
The regional ethics board of the University of Lund approved the
study (No. 514/2007).
Results
Characteristics
Mean (S.D.) age for cases and controls was 43 (11)yrs and mean
(S.D.) disease duration (time since debut) for the cases were 20
(11)yrs. The mean (S.D.) follow-up time for sick leave was 6.4
(1.6)yrs for both cases and controls. Forty patients (33%) had
ever been treated for uveitis and 26 patients (21%) had been
treated with TNF-inhibitors (Table 1).
Sick leave
During the follow-up period there were more AS cases than
controls that were registered for sickness benefit (52 vs 36%,
P<0.01) and sickness compensation (42 vs 11%, P<0.001).
Thirty percent of the cases and 58% of the controls had no
registered sick leave days at all during the follow-up period.
AS patients had an increased risk for sick leave (i.e. either sick-
ness benefit and/or sickness compensation) compared with
controls with a relative risk of 1.8; 95% CI 1.5, 2.1 over the
7-yr period.
The increased risk for sick leave for patients younger than
45 yrs was 2.1; 95% CI 1.6, 2.8, and for patients older than 45yrs
1.6; 95% CI 1.3, 2 (P-value for difference¼0.07). This indicates
that age tends to weaken the effect of the AS disease on sick leave.
AS patients had more days of sick leave than controls. Median
[quartile (Q) 1, Q3] value for number of days with sick leave of
any rate (25, 50, 75 and 100%) per year was 50 (0, 317) for cases
and 0 (0, 11) for controls. Median (Q1, Q3) value for sick leave
rate adjusted to number of days with 100% sick leave per year was
43 (0, 199) for cases and 0 (0, 10) for controls. The difference
in number of days with sick leave (days with sickness benefit or
Day 1
Waiting period
Days 2 to 14
Sick pay from the
employer
Day 1 Day 15
Days 15 to ~ 365
(approximately; indefinite 
cut-  off)
Sickness benefit
from the Social Insurance 
Agency
After ~ 365 days of sick leave
Sickness compensation 
from the Social Insurance Agency
Time
FIG. 1. Description of different forms of benefits for individuals with sick leave
according to the Swedish Social Insurance system.
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and controls was median 30 days; 95% CI 2, 72.
The proportion of persons with sick leave increased with age—
persons 45yrs and older had a higher level of sick leave than
persons younger than 45yrs (Fig. 2).
Post hoc analysis
The characteristics of the subgroup of patients with AS (n¼61)
with BASDAI and BASFI data available did not substantially
differ from the subjects without such data (Table 1). Mean
BASDAI and BASFI was 4 and 3.7, respectively. Median (Q1,
Q3) value for number of days with sick leave of any rate (25, 50,
75 and 100%) per year was 49 (0, 307) and median (Q1, Q3) value
for sick leave rate adjusted to number of days with 100% sick
leave per year was 38 (0, 232).
There was no statistically significant correlation between
number of sick leave days and BASDAI (rs¼0.15) or BASFI
(rs¼0.18), respectively.
Discussion
In contrast to what many clinicians assume, patients with AS have
increased sick leave. Our population-based case–control study,
which is to the best of our knowledge the first study presenting
Swedish sick leave data for this patient category, shows an 80%
increased risk of sick leave over a 7-yr period. The sick leave data
were collected from an independent, reliable and identical source
for both cases and controls as sick leave over 14 days for all
residents leading to compensation is continuously registered by
the Swedish Social Insurance Agency.
Our findings are in concordance with earlier reports, [7, 8, 12,
22] and some of these have presented data allowing interpreta-
tion of work participation in relation to the general population.
Boonen et al. [7] described that the risk for withdrawal from work
in the Netherlands was about 3-times higher in patients with AS,
and that work disability in three European countries was higher
than expected in the general population [8]. Mau et al. [22] com-
pared employment rates in different rheumatic diseases with the
general German population and found that there were differences,
but smaller than expected, especially in AS. However, the differ-
ences increased with longer disease duration [22]. The employment
rate in patients with AS was higher than in patients with RA from
the German rheumatological database [23]. Due to heterogeneity
of populations studied, differences in definitions of end-points
and methodology used, as well as in labour markets and social
security systems, comparisons between countries may be difficult
to interpret.
Since patients in our study were recruited from rheumatological
specialist care they can be expected to have a higher disease
activity and to be more severely affected and as all the included
patients fulfilled the New York criteria for the diagnosis of AS,
early disease might not be included. The sick leave may therefore
not be representative for the whole spectrum of disease [24].
The mechanisms causing the increased sick leave are multiple,
with contribution by disease-related factors, work-related factors,
sociodemographic factors, mental factors as well as coping styles
[7, 12, 25–29]. In our study, sick leave was not associated with
disease activity or function, which could indicate that other, not
evaluated, factors influence the degree of sick leave [25, 27–29].
During recent years effective anti-inflammatory and disease-
modifying treatment with TNF inhibitors have become increas-
ingly available. In fact, 21% of our patients had received such
therapy, which may have affected their sick leave. However, serv-
ing as a limitation, our study sample was too small to evaluate
if TNF inhibitor treatment was associated with work disability.
Also, our data do not include shorter periods (up to 14 days)
of sick leave as these periods are directly compensated by the
employer and never get registered by the Swedish Social Security
Agency. It is possible that AS patients also have an increase of
such brief periods of sick leave compared with controls, and
therefore our estimates of increased risk may be biased towards
the null.
To sum up, we have demonstrated that AS patients in Sweden
have an increased sick leave level, despite the introduction of
FIG. 2. Proportions of patients with AS and controls with sickness benefit and sickness compensation of any extent (25, 50, 75 and 100%) during the follow-up period.
Groups are divided based on the individuals being younger than 45yrs and 45yrs or older at the time of the investigation.
TABLE 1. Characteristics of the patients with AS (the main group, n¼122) the
controls (n¼366) and the subgroup of patients with AS (n¼61) with BASDAI and
BASFI data available
Characteristics AS patients
n¼122
Controls
n¼366
AS patients
(subgroup) n¼61
Women, n (%) 21 (17) 44 (17) 10 (16)
Age, mean (S.D.)
a, years 43 (11) 43 (11) 44 (11)
Disease duration, mean (S.D.)
a, years 20 (11) – 20 (13)
Follow-up time, mean (S.D.), years 6.4 (1.6) 6.4 (1.6) 6.8 (0.7)
HLA-B27, n (%)
Positive 67 (55) – 29 (48)
Negative 5 (4) – 3 (4)
Not tested 50 (41) – 29 (48)
Uveitis, n (%) 40 (33) – 21 (34)
Treated with TNF-inhibitors, n (%) 26 (21) – NA
BASDAI, mean (S.D.) NA – 4 (2.4)
BASFI, mean (S.D.) NA – 3.7 (2.4)
aAt start of follow-up. NA¼not assessed.
Sick leave in AS 291TNF inhibitors in the treatment arsenal. We also demonstrate
the large potential for work disability studies that is possible by
using the Swedish population-based registers for health care
and social insurance benefits [30, 31]. These registers form an
exciting possibility for evaluation of treatment interventions,
such as team-based rehabilitation [32] and biologic pharmacolo-
gical treatment [16].
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